COVID-19 Vaccine Algorithm

Is the patient eligible for a primary, additional, or booster dose?






Table 3: Definition of Occupations at Increased Risk for COVID-19 Exposure and Transmission

≥2 weeks), alkylating agents,

antimetabolites, transplant-related

immunosuppressive drugs, cancer

chemotherapeutic agents classified

as severely immunosuppressive,

tumor-necrosis (TNF) blockers,

and other biologic agents that

are immunosuppressive or

immunomodulatory

· First responders (healthcare workers, firefighters, police, congregate care staff)

Moderate or severe primary

syndrome, Wiskott-Aldrich

syndrome)

immunodeficiency (e.g., DiGeorge

- · Education staff (teachers,
- Food and agriculture workers
- · Manufacturing workers
- Corrections workers
- U.S. Postal Service workers
- Public transit workers

- support staff, daycare workers)
- Grocery store workers

Smoking, current or former

Solid organ or blood stem

Stroke or cerebrovascular

disease, which affects

blood flow to the brain

Substance use disorders

cell transplant

Dementia or other

Down syndrome

Heart conditions

hypertension)

(such as heart failure.

cardiomyopathies or

coronary artery disease,

neurological conditions

Diabetes (type 1 or type 2)

*List could be updated in the future

The material and information contained in this publication is believed to be current as of the date included on this document. The American Pharmacists Association assumes no responsibility for the accuracy, timeliness, errors or omission contained herein. Links to any sources do not constitute any endorsement of, validity, or warranty of the information contained on any site. The user of these materials should not under any circumstances solely rely on, or act based on this publication. Pharmacy professionals retain the responsibility for using their own professional judgment and practicing in accordance with all rules, regulations, and laws

Reference CDC's Clinical Considerations for Use of COVID-19 Vaccines for detailed information. Disclaimer: Information related to the COVID-19 pandemic is changing rapidly and continuously.

(J&J) (0.5 mL) at least 6 months after the 2nd

dose in the primary series.

governing the pharmacy practice within their jurisdiction.

recommended

at this time.

UPDATED OCTOBER 26, 2021. COPYRIGHT © 2021, AMERICAN PHARMACISTS ASSOCIATION. ALL RIGHTS RESERVED.